Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. - Wikidata - wikimedia - TriplyDB

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.

http://www.wikidata.org/entity/Q36947391

about

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis.Pharmacotherapy of end-stage renal disease.Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study The cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet.A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM)Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism.Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study.Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges.Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?Diseases of the parathyroid gland in chronic kidney disease.Vascular and valvular calcification in chronic peritoneal dialysis patients.Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.Cinacalcet hydrochloride for the treatment of hyperparathyroidism.Safety and tolerability of paricalcitol in patients with chronic kidney disease.Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism.Emerging drugs for secondary hyperparathyroidism.Advances in pharmacotherapy for secondary hyperparathyroidism.Cinacalcet and Clinical Outcomes in Dialysis.Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.Cinacalcet: the chemical parathyroidectomy?Long-Term Hypoparathyroidism and Hypophosphatemia in Dialysis Patients Reversible bone pain and symmetric bone scan uptake in a dialysis patient treated with cinacalcet: a case report.Which vitamin D in CKD-MBD? The time of burning questions.Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.

P2860

Q24187385-834C306E-1A4B-44B4-A301-04466352290D Q26851487-320D03D9-F9AA-49A6-B860-D33309CFDC75 Q28079300-240E787A-7386-4C75-9167-ADD3F31E3822 Q28484646-5D4C8D16-DEFA-4AD6-82A2-FFE0E4E08199 Q30251450-E66E18AF-0F36-4069-AC1F-B7B1F4E2DFE0 Q33531889-0064F989-98A0-4A64-B3C1-464FCBD81279 Q33571321-F4AB5FAB-7178-4A0F-A85F-C4D2BAC29746 Q34293730-98848780-66C0-465E-AECF-D46715373BEC Q34362759-0A016A24-7349-47A6-A541-0725C239EBE2 Q34739121-F5879A83-393B-4CA2-9C7E-5A98D5BE455D Q35635182-E84B06FD-CCAD-4F04-BBE2-D5DBAD774D44 Q35682192-193967BC-DCC4-437C-B591-DE249A45BEF0 Q35920190-549DE44A-ED8B-47C4-A8F6-81FC79DEECBB Q35983513-AC54CCFE-B569-48A9-AE99-ACF58F64026D Q36121519-D6BE96BD-F2B2-4E4E-A080-74684F44BE22 Q36129859-D729D269-1599-4D46-814B-FD9B0FB1E5BE Q36193227-BE220097-D8D7-4D80-84B1-832D9DB68DB0 Q36199558-A8B1C5A9-999E-40A3-BA79-E426107AE665 Q36432849-55E038DA-0520-4C49-A1CD-8BF14D78B28C Q36994093-59EF786F-72A0-4A7A-931E-5D296CD8A4FC Q37310824-662BBBA0-2C75-4DB0-89D4-4D9A80E56612 Q37638757-2344B110-ED90-408B-8060-7B4CA660B892 Q37807991-38546EB4-9559-4714-BD78-527193571DA2 Q37891153-C665EE0B-5614-4D71-9F99-D525E51C1E50 Q37912038-D44B1962-D755-412B-A80D-4EBF8382B8F0 Q37914009-4944B741-4C30-446E-B1B4-E5BE56826B50 Q37916534-A5A26BEB-6106-44D4-A924-9B123B5B4F54 Q38085702-43D696A8-7D08-406A-9C8B-692B7B3DA35D Q38101995-C66ED34A-D8BB-446D-9F32-7833B33BC691 Q38111948-E8096D54-9AA6-4F5A-8C8B-13A70AEB42F1 Q38141236-A3A48F06-E160-4C36-BDA1-7D03324C2D35 Q38363615-44108D57-2CA5-48B3-BD3A-CEA82EACF89E Q38544533-B0C25694-B36C-483E-80FC-F4B57C5A8F18 Q38565049-24515437-5D6B-47E8-9BF4-49415770CA4E Q39374348-802E10FC-CCAA-448F-95F0-7D16432C4998 Q39719456-AC34FDCD-8B52-4E98-BF45-33B2B7F0675D Q40479039-48648804-50F7-4428-AB68-BB4B89E290B0 Q42194890-071058BC-0BB7-4BFC-A679-E97EE98DF1B4 Q42562972-EE3F4BF3-CCA0-41B6-9937-033679EB28C0 Q42683242-61722E39-582F-4E1F-8516-D87154488667

P2860

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.

http://www.wikidata.org/entity/Q36947391

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Cinacalcet HCl and concurrent ...... ne: the ACHIEVE study results.

@en

type

label

Cinacalcet HCl and concurrent ...... ne: the ACHIEVE study results.

@en

prefLabel

Cinacalcet HCl and concurrent ...... ne: the ACHIEVE study results.

@en

P1433

Q36947391-64F91573-D6D5-49C9-9CCF-3BF4EC88D5A1

P1476

Q36947391-D89C9D40-9490-45DA-A670-549A18FF4F7B

P2093

Q36947391-02B27E97-FB0F-40C5-9DAD-3C9537CC7322

Q36947391-2A11A459-1D0D-484E-AAF2-D2F0BCF0B77D

Q36947391-43BA161D-EF31-4532-AF7C-F5B24E5C1197

Q36947391-49E446DE-D812-4314-9100-5B91E87181FF

Q36947391-5221562E-144E-4027-AE1E-937C9EE810DC

Q36947391-7570AF37-A876-48F3-B85E-9E942399C376

Q36947391-8C1B0D2A-8538-4E7A-B48B-C30A0650EC56

Q36947391-CE7BA455-F668-417F-A070-7EA3C7C68432

Q36947391-F531D782-04D7-41DC-AE3E-78E3D582C3B8

Q36947391-F91058BF-83FE-41F2-AA7A-8F1F6C67FED3

P2860

Q36947391-0259D161-1E96-41AF-9B70-06E36DA2BFC6

Q36947391-0C467D6E-B475-47CB-9BDC-B4283AE17490

Q36947391-202D90B8-359F-4109-B219-A42106275B39

Q36947391-2C843ACB-FEE5-401D-85AE-217A30D30EE4

Q36947391-36C9CFB0-0B06-47B5-8792-56A3FF12AAC3

Q36947391-43EC2A05-5994-44E8-AB6F-B1D8ABC02746

Q36947391-452243AA-C2CC-4466-9C16-E9176AC47E18

Q36947391-4B05AD39-675F-4D44-AF95-7FDCF0BB17CC

Q36947391-6A90B7DC-93AF-4BD6-8335-217C362CC7AA

Q36947391-7BC960FC-5328-48A5-AB4E-D83EC43F38D9

P304

Q36947391-BA87689E-B13A-4133-AA21-3C3420206A8E

P31

Q36947391-A2B19190-D6B5-4F14-B858-1244A84846A8

P356

Q36947391-7BBED4E7-C6D7-40B2-88EE-1775696762CB

P433

Q36947391-C12C6EF9-6697-4E25-BD91-2CD260B0FA57

P478

Q36947391-3F47572A-035D-4DF7-B374-BCFA4C315873

P577

Q36947391-429DE0A4-B89E-441D-B0C9-258E2795516C

P698

Q36947391-7482B152-9881-43B4-8E9A-CE6E0F47B265

P921

Q36947391-0FFC33CD-6F1D-4216-B916-B730D27B0AFB

Q36947391-12AD1C4E-104A-46C2-9E7D-026FB84EF561

Q36947391-F36F98D1-2570-4038-A6CB-9832EF30A708

Q36947391-f404489a-778d-4c7a-813f-0df0c46ea402

P932

Q36947391-ED842EC1-321A-475F-94ED-5E290CA7DF9F

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Cinacalcet HCl and concurrent ...... ne: the ACHIEVE study results.

@en

P2093

Chaim Charytan

http://www.w3.org/2001/XMLSchema#string

Dalila B Corry

http://www.w3.org/2001/XMLSchema#string

Kenneth Rappaport

http://www.w3.org/2001/XMLSchema#string

Michael Roppolo

http://www.w3.org/2001/XMLSchema#string

Steven Fishbane

http://www.w3.org/2001/XMLSchema#string

Steven L Vicks

http://www.w3.org/2001/XMLSchema#string

Stewart Turner

http://www.w3.org/2001/XMLSchema#string

Warren B Shapiro

http://www.w3.org/2001/XMLSchema#string

William G Goodman

http://www.w3.org/2001/XMLSchema#string

Xiang Ling

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.

Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.

Parathyroid hormone: new assays, new receptors.

Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure.

Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism.

Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group.

Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study.

Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.

P304

1718-1725

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.01040308

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18945995

http://www.w3.org/2001/XMLSchema#string

P921

hyperparathyroidism

P932

2572296

http://www.w3.org/2001/XMLSchema#string